At 3:30 PM today, Shanghai Mental Health Center ushered in the breakthrough in depression treatment: in the Ward of Clinical Diagnosis and Treatment Center for Mood Disorders at the National Psychiatric Center, a patient with suicidal ideation of depression under the guidance of the doctor, smoothly accepted the nasal spray esketamine hydrochloride "first spray" treatment.
The Clinical Diagnosis and Treatment Center for Mood Disorders has formulated the relevant evaluation process and medical management norms for the implementation of the treatment plan, which is the first depression patient with suicide to receive the standard esketamine hydrochloride spray treatment.
Among patients with depression, compared with patients with depression without suicidal ideation or behavior, the current acute phase treatment situation of patients with suicide is not optimistic. The existing treatment methods work slowly, and the potential suicide risk always troubles depression patients and their families. Traditional drug treatment cannot meet the urgency of depression patients with suicide, the standard clinical application of esketamine hydrochloride provides a new choice for such patients, the drug by antagonistic N-methyl-D aspartate receptor play antidepressant effect, nasal spray administration can quickly alleviate the symptoms of adult depression patients with acute suicidal ideation or behavior.

The Mood Disorders Department of Shanghai Mental Health Center has been established for more than 21 years ago, and now it has been developed into the Clinical Diagnosis and Treatment Center for Mood Disorders at the National Psychiatric Center. The Center is committed to leading the research in the field of depression to clinical transformation, and seeking breakthroughs on the basis of the treatment standardization. In the use of esketamine hydrochloride, the clinical diagnosis and treatment center of mood disorders strictly follows the treatment norms, and evaluates and uses the medication under the supervision of professional medical staff, so as to ensure that patients can get scientific, reasonable and safe treatment. The successful "first injection" of esketamine hydrochloride is an important exploration and practice of the center in the field of depression treatment, and also brings new hope for the rapid treatment of depression patients with clinical needs.